ARTICLES BY BERNHARD J. PAUL
-
![Award-Winning-iStock-1223896882]( "How To Make Your CDMO Selection An Award-Winning Event")
How To Make Your CDMO Selection An Award-Winning Event9/23/2020There are many considerations when it comes to selecting a partner. Cost is always a major factor, but it’s important to also consider some of the other project requirements and how well they match the skills of any particular CMO.
-
![Question-Pills-Hand]( "5 Questions To Ask Your CDMO: #3 — How Do You Control Solid Form?")
5 Questions To Ask Your CDMO: #3 — How Do You Control Solid Form?11/13/2018It is critically important for many of today’s drug candidates to select the right physical form early in development to ensure the active ingredient can be delivered in the optimum fashion.
-
![Fear Factors]( "5 Questions To Ask Your CDMO: #2 – Can You Tell Me About A Project Where Things Went Wrong?")
5 Questions To Ask Your CDMO: #2 – Can You Tell Me About A Project Where Things Went Wrong?10/2/2018Taking a potential drug from candidate selection through clinical development and eventual commercialization is a challenging process. It is not a question of if something unexpected will happen, but when. And when the inevitable problem occurs, how will your CDMO tackle this situation?
-
![5 Questions To Ask Your CDMO: #1 – How Integrated Are Your Services In Practice?]( "5 Questions To Ask Your CDMO: #1 – How Integrated Are Your Services In Practice?")
5 Questions To Ask Your CDMO: #1 – How Integrated Are Your Services In Practice?9/5/2018You need your outsourced services to be fully integrated to receive the maximum benefit to your projects. But there is a famous quote: "In theory, there's no difference between practice and theory. In practice, there is.” In this article, we help you determine if you are getting a fully integrated service offering.
Bernhard J. Paul
Bernhard J Paul, Ph.D. is the founder and principal consultant at Carinth Consulting LLC, a drug development consulting firm based in the Boston area. Paul has worked within biotech and for multiple CDMOs in the U.S. and Europe, and he uses his extensive experience to advise companies on all aspects of small molecule development and strategy. Paul is the author of 21 U.S. patents and multiple peer reviewed articles. He holds a Ph.D. from the University of Florida and an undergraduate degree from the University of Graz, Austria. He can be contacted at bernhard.paul@carinthconsulting.com.